"New AIDS Drug Poised to Move Into Development"

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

"New AIDS Drug Poised to Move Into Development"

Science (12/20/91) Vol. 254, No. 5039, P. 1715
Hamilton, David P.

Abstract: A drug set aside last summer by its manufacturer, Hoffman-La Roche, is about to return to clinical trials. Hoffman-La Roche's final decision on a licensing partner for Ro 24-7429, the antiviral compund that uniquely attacks HIV, was immenent, according to insiders. The comany decided last May to discontinue developing Ro 24-7429, choosing instead to concentrate on two other promising antiviral drugs that are more completely developed. However, recent reports suggesting that HIV can rapidly develop resistance to many of the possible treatments have increased the need to find compuounds that use a different device. Before Hoffman-La Roche mothballed the drug, a continuing single clinical trial at the Johns Hopkins University to test the toxicity of Ro 24-7429 has so far found it to be safe. Federal AIDS officials are eager to discover if the drug will also be effective.

911220
AD912269

Copyright © 1991 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.